Nature Communications (Aug 2018)
BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma
- Kyren A. Lazarus,
- Fazal Hadi,
- Elisabetta Zambon,
- Karsten Bach,
- Maria-Francesca Santolla,
- Julie K. Watson,
- Lucia L. Correia,
- Madhumita Das,
- Rosemary Ugur,
- Sara Pensa,
- Lukas Becker,
- Lia S. Campos,
- Graham Ladds,
- Pentao Liu,
- Gerard I. Evan,
- Frank M. McCaughan,
- John Le Quesne,
- Joo-Hyeon Lee,
- Dinis Calado,
- Walid T. Khaled
Affiliations
- Kyren A. Lazarus
- Department of Pharmacology, University of Cambridge
- Fazal Hadi
- Department of Pharmacology, University of Cambridge
- Elisabetta Zambon
- Department of Pharmacology, University of Cambridge
- Karsten Bach
- Department of Pharmacology, University of Cambridge
- Maria-Francesca Santolla
- Department of Pharmacology, University of Cambridge
- Julie K. Watson
- WT-MRC Stem Cell Institute, University of Cambridge
- Lucia L. Correia
- Department of Biochemistry, University of Cambridge
- Madhumita Das
- MRC Toxicology Unit, Lancaster Road
- Rosemary Ugur
- Department of Pharmacology, University of Cambridge
- Sara Pensa
- Department of Pharmacology, University of Cambridge
- Lukas Becker
- Department of Pharmacology, University of Cambridge
- Lia S. Campos
- Wellcome Trust Sanger Institute
- Graham Ladds
- Department of Pharmacology, University of Cambridge
- Pentao Liu
- Wellcome Trust Sanger Institute
- Gerard I. Evan
- Department of Biochemistry, University of Cambridge
- Frank M. McCaughan
- Department of Biochemistry, University of Cambridge
- John Le Quesne
- MRC Toxicology Unit, Lancaster Road
- Joo-Hyeon Lee
- WT-MRC Stem Cell Institute, University of Cambridge
- Dinis Calado
- The Francis Crick Institute
- Walid T. Khaled
- Department of Pharmacology, University of Cambridge
- DOI
- https://doi.org/10.1038/s41467-018-05790-5
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 11
Abstract
Amongst the non-small cell lung cancers, to date, lung squamous cell carcinoma remains the most challenging to treat. Here the authors report BCL11A as an important factor which together with SOX2 can drive lung squamous cell carcinoma development and highlight a potential novel therapeutic candidate for this devastating disease.
